Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case

MÜNGEN E., Bajin I. Y., Oz S., Gunbey C., Anlar B., Aydin B.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, cilt.44, sa.7, ss.402-404, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 7
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1097/mph.0000000000002473
  • Dergi Adı: JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.402-404
  • Anahtar Kelimeler: ifosfamide-induced encephalopathy, thiamine, neurotoxicity, ifosfamide, METHYLENE-BLUE, PREVENTION
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Ifosfamide is an important chemotherapeutic agent used in the therapeutic protocols of many malignant tumors. Central nervous system toxicity of ifosfamide manifests with encephalopathy in 10% to 30% of patients treated with ifosfamide. Thiamine and methylene blue have been reported beneficial in the treatment and prevention of ifosfamide-induced encephalopathy (IIE). We describe an episode of encephalopathy developed at the third cycle of ifosfamide treatment in a child with Ewing sarcoma. With the administration of thiamin, the encephalopathy resolved and no episode was noted during subsequent courses of ifosfamide. Previous use of cisplatin, concomitant use of opioids, low levels of serum albumin and hemoglobin, and elevated levels of serum creatinine are potential risk factors for IIE. The current case illustrates the possibility of IIE even in the absence of such additional risk factors, treated successfully with thiamin and draws attention to the need for close neurological monitorization of patients treated with ifosfamide.